膝下旁路术、腔内治疗与截肢术在慢性肢体威胁性缺血中的费用比较
BASIL前瞻性队列研究纳入60例慢性肢体威胁性缺血患者,分别接受膝下静脉旁路术、膝下最佳腔内治疗或大截肢,比较12个月内手术人力成本和住院总费用。结果显示腔内治疗费用最低,截肢和旁路术费用较高。
要点
- 膝下腔内治疗12个月总住院费用最低(£12,298)
- 大截肢和膝下旁路术总费用均高于腔内治疗
- 旁路术手术人力成本最高,与手术时间和人员需求增加有关
核心结论
- 在12个月时间范围内,大截肢和膝下旁路术的手术人力成本及总住院费用均高于膝下最佳腔内治疗。
研究设计与样本
- BASIL前瞻性队列研究纳入60例连续慢性肢体威胁性缺血患者,其中膝下旁路术20例、膝下最佳腔内治疗20例、大截肢20例(股动脉截肢10例、胫骨截肢10例),比较索引住院及随后12个月的费用。
主要发现
- 手术人力成本旁路术最高(£2551;95%CI £1934-£2807),其次为大截肢(£1130;95%CI £1046-£1297)和腔内治疗(£329;95%CI £242-£390),P < .001。
- 索引住院费用大截肢最高(£13,320;95%CI £8986-£18,616),旁路术为£8714(95%CI £6097-£11,973),腔内治疗为£4813(95%CI £3529-£6097),P < .001。
- 索引住院加随后12个月住院总费用腔内治疗最低(£12,298;95%CI £6961-£15,439),旁路术为£20,401(95%CI £12,071-£23,926),大截肢为£26,327(95%CI £17,653-£30,458),P < .001。
临床怎么用
- 在资源分配和成本效益评估中,膝下腔内治疗可能相比旁路术和大截肢在12个月内节省住院费用。
局限性
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic limb-threatening ischemia (CLTI) is a growing global problem due to the widespread use of tobacco and increasing prevalence of diabetes. Although the financial consequences are considerable, few studies have compared the relative cost-effectiveness of different CLTI management strategies. The Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 trial is randomizing patients with CLTI to primary infrapopliteal (IP) vein bypass surgery (BS) or best endovascular treatment (BET) and includes a comprehensive within-trial cost-utility analysis. The aim of this study is to compare over a 12-month time horizon, the costs of primary IP BS, IP best endovascular treatment (BET), and major limb major amputation (MLLA) to inform the BASIL-2 cost-utility analysis. METHODS: We compared procedural human resource (HR) costs and total in-hospital costs for the index admission, and over the following 12-months, in 60 consecutive patients undergoing primary IP BS (n = 20), IP BET (n = 20), or MLLA (10 transfemoral and 10 transtibial) for CLTI within the BASIL prospective cohort study. RESULTS: Procedural HR costs were greatest for BS (BS £2551; 95% confidence interval [CI], £1934-£2807 vs MLLA £1130; 95% CI, £1046-£1297 vs BET £329; 95% CI, £242-£390; P < .001, Kruskal-Wallis) due to longer procedure duration and greater staff requirement. With regard to the index admission, MLLA was the most expensive due to longer hospital stay (MLLA £13,320; 95% CI, £8986-£18,616 vs BS £8714; 95% CI, £6097-£11,973 vs BET £4813; 95% CI, £3529-£6097; P < .001, Kruskal-Wallis). The total cost of the index admission and in-hospital care over the following 12 months remained least for BET (MLLA £26,327; 95% CI, £17,653-£30,458 vs BS £20,401; 95% CI, £12,071-£23,926 vs BET £12,298; 95% CI, £6961-£15,439; P < .001, Kruskal-Wallis). CONCLUSIONS: Over a 12-month time horizon, MLLA and IP BS are more expensive than IP BET in terms of procedural HR costs and total in-hospital costs. These economic data, together with quality of life data from BASIL-2, will inform the calculation of incremental cost-effectiveness ratios for different CLTI management strategies within the BASIL-2 cost-utility analysis.
引用
- Popplewell MA, Andronis L, Davies HOB, et al. Procedural and 12-month in-hospital costs of primary infra-popliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia. J Vasc Surg. 2021. PMID: 34481898. doi:10.1016/j.jvs.2021.07.232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。